There is pessimism on European financial markets today. Contracts on the DE40 are down over 0.4% today, while the EU50 is falling by more than 0.8%. Contracts on the FRA40 and ITA40 are also performing poorly, declining by nearly 0.9% and 0.8%, respectively. The market is reacting this way to the upcoming series of meetings concerning a potential ceasefire in Ukraine. The macroeconomic calendar for the rest of the day remains empty; therefore, investors are fully focusing their attention on the visit of the highest-ranking European politicians to the White House.
Source: xStation
Currently observed volatility in the broader European market. Source: xStation
The German DE40 index is losing 0.4% during today’s session and is very close to support levels defined by the 25-day and 50-day exponential moving averages (the green and purple lines on the chart, respectively). At this moment, both averages appear to be strong support that could maintain the upward trend, but it should be remembered that the coming days could be crucial for European markets.
Source:
xStation
Company news:
Rheinmetall (RHM.DE) is gaining over 3% today. This is a consequence of ongoing peace talks regarding the conflict in Ukraine. Additionally, the company’s stock price is supported by discussions between Trump and the European Union on defense matters, which could translate into increased orders for defense companies.
Source: xStation
RENK Group (R3NK.DE) is rising by nearly 2.5% after confirming a strong order book and stable operating margin despite a difficult geopolitical environment. Additionally, the company benefits from investor sentiment closely watching European countries’ discussions with the U.S. administration regarding peace in Ukraine and security issues on the continent. Renk, as a supplier of specialized solutions for the defense industry, could benefit from potential demand growth related to the intensification of the conflict and increased transatlantic cooperation in defense.
Source: xStation
Novo Nordisk (NOVOB.DK) surged over 5% following FDA approval for the use of the drug Wegovy in treating MASH (non-alcoholic steatohepatitis). This decision undoubtedly opens new opportunities for the company by expanding its portfolio with drugs for patients suffering from liver diseases.
Source: xStation
Vestas (VWS.DK) is up more than 15% today, supported by favorable legislative changes in the U.S. At the same time, positive sentiment in the renewable energy sector and expectations of infrastructure investments in the European Union further support the wind turbine manufacturer’s stock price.
Source: xStation
Company news from firms listed on the German exchange. Source: Bloomberg Financial Lp
Wheat drops amid higher than expected WASDE report
Alibaba sell-off extends amid White House national security concerns📌
US Earnings Season Summary 🗽What the Latest FactSet Data Shows
3 markets to watch next week (14.11.2025)
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
